Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Toni K Choueiri

19PUBLICATIONS
104CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersNgā tāngata, te porihanga me ngā hapori o te Māori kāore anō kia whakarōpūtia i wāhi kē (Māori peoples, society and community not elsewhere classified)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

Sort by Publication Date:
|Jul 01, 2026
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

|Mar 30, 2026
Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors.

Yen-Chou Chen, Mandar A Aras, Brian I Rini

|Mar 23, 2026
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Rana R McKay, Archana Ajmera, Michael B Atkins

|Feb 18, 2026
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.

Douglas B Johnson, Amin H Nassar, Ayesha Aijaz

|Dec 13, 2025
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Rana R McKay, Sumanta Pal, Wanling Xie

|Aug 01, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.

Brian I Rini, Elizabeth R Plimack, Viktor Stus

Pageof 4

Frequent Collaborators

8 joint publications

Toni K Choueiri

7 joint publications

Michael B Atkins

6 joint publications

Robert Motzer

3 joint publications

Thomas Powles

3 joint publications

Kathryn E Beckermann

2 joint publications

David Braun

2 joint publications

Sumanta K Pal

2 joint publications

John Haanen

2 joint publications

Tian Zhang

2 joint publications

Laurence Albiges

Frequent Collaborators

8 joint publications

Toni K Choueiri

7 joint publications

Michael B Atkins

6 joint publications

Robert Motzer

3 joint publications

Thomas Powles